Stephen Yc Tong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3505765/publications.pdf

Version: 2024-02-01

209 papers	4,993 citations	101384 36 h-index	143772 57 g-index
213 all docs	213 docs citations	213 times ranked	5054 citing authors

#	Article	IF	Citations
1	Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. American Journal of Obstetrics and Gynecology, 2022, 226, S1157-S1170.	0.7	47
2	A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeksâ€™ gestation in pregnancies destined to deliver small for gestational age infants. Placenta, 2022, 117, 1-4.	0.7	7
3	Circulating Activin A is elevated at 36Âweeksâ€™ gestation preceding a diagnosis of preeclampsia. Pregnancy Hypertension, 2022, 27, 23-26.	0.6	3
4	Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer. Gynecologic Oncology Reports, 2022, 39, 100894.	0.3	3
5	Clinical tools and biomarkers to predict preeclampsia. EBioMedicine, 2022, 75, 103780.	2.7	71
6	Estimation of neonatal body fat percentage predicts neonatal hypothermia better than birthweight centile. Journal of Maternal-Fetal and Neonatal Medicine, 2022, , 1-8.	0.7	2
7	Circulating SPINT1 Is Reduced in a Preeclamptic Cohort with Co-Existing Fetal Growth Restriction. Journal of Clinical Medicine, 2022, 11, 901.	1.0	4
8	Circulating serine peptidase inhibitor Kunitz type 1 (SPINT1) in the second trimester is reduced among pregnancies that end in low birthweight neonates: cohort study of 2006 pregnancies. American Journal of Obstetrics & Gynecology MFM, 2022, 4, 100618.	1.3	1
9	Maternal factors during pregnancy influencing maternal, fetal and childhood outcomes: Meet the Guest Editors. BMC Medicine, 2022, 20, 114.	2.3	2
10	Low-Dose Aspirin for Preventing Birth of a Small-For-Gestational Age Neonate in a Subsequent Pregnancy. Obstetrics and Gynecology, 2022, Publish Ahead of Print, .	1.2	1
11	Cerebral biomarkers in neurologic complications of preeclampsia. American Journal of Obstetrics and Gynecology, 2022, 227, 298.e1-298.e10.	0.7	7
12	PSG7 and 9 (Pregnancyâ€Specific Î²â€1 Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia. Journal of the American Heart Association, 2022, 11, e024536.	1.6	5
13	Time to resolution of tubal ectopic pregnancy following methotrexate treatment: A retrospective cohort study. PLoS ONE, 2022, 17, e0268741.	1.1	5
14	Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. American Journal of Obstetrics and Gynecology, 2021, 224, 95.e1-95.e12.	0.7	71
15	Nanoparticles in pregnancy: the next frontier in reproductive therapeutics. Human Reproduction Update, 2021, 27, 280-304.	5.2	42
16	Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia. Placenta, 2021, 105, 32-40.	0.7	8
17	DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia. Scientific Reports, 2021, 11, 5540.	1.6	8
18	Aspirin to prevent pre-eclampsia. Drug and Therapeutics Bulletin, 2021, 59, 56-59.	0.3	3

#	Article	IF	Citations
19	Risk of major labour-related complications for pregnancies progressing to 42 weeks or beyond. BMC Medicine, 2021, 19, 126.	2.3	4
20	Nicotinamide and its effects on endothelial dysfunction and secretion of antiangiogenic factors by primary human placental cells and tissues. Placenta, 2021, 109, 28-31.	0.7	1
21	Maternal circulating SPINT1 is reduced in small-for-gestational age pregnancies at 26 weeks: Growing up in Singapore towards health outcomes (GUSTO) cohort study. Placenta, 2021, 110, 24-28.	0.7	7
22	Elevated Circulating and Placental SPINT2 Is Associated with Placental Dysfunction. International Journal of Molecular Sciences, 2021, 22, 7467.	1.8	9
23	Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia. Journal of Clinical Medicine, 2021, 10, 3384.	1.0	5
24	Pre-eclampsia. Lancet, The, 2021, 398, 341-354.	6.3	365
25	Revisiting blood pressure thresholds to define hypertension during pregnancy: is 140/90 mmHg too high?. The Lancet Global Health, 2021, 9, e1041-e1042.	2.9	3
26	Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. Scientific Reports, 2021, 11, 16595.	1.6	5
27	LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast. Pregnancy Hypertension, 2021, 25, 255-261.	0.6	2
28	Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker. Journal of the American Heart Association, 2021, 10, e020302.	1.6	17
29	Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. BMJ, The, 2021, 374, n2103.	3.0	46
30	Severe maternal morbidity in the Asia Pacific: a systematic review and meta-analysis. The Lancet Regional Health - Western Pacific, 2021, 14, 100217.	1.3	7
31	1295School age outcomes in IVF-conceived children compared with controls: a population linkage study. International Journal of Epidemiology, 2021, 50, .	0.9	0
32	Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling. Placenta, 2021, 114, 22-28.	0.7	5
33	Measuring circulating miRNAs in early pregnancy could identify fetusesâ€™ destined to undergrow and be at increased risk of stillbirth. EBioMedicine, 2021, 63, 103172.	2.7	0
34	Accelerated fetal growth velocity across the third trimester is associated with increased shoulder dystocia risk among fetuses who are not large-for-gestational-age: A prospective observational cohort study. PLoS ONE, 2021, 16, e0258634.	1.1	6
35	NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast. Scientific Reports, 2021, 11, 20670.	1.6	1
36	Evidence of Neuroinflammation and Bloodâ€“Brain Barrier Disruption in Women with Preeclampsia and Eclampsia. Cells, 2021, 10, 3045.	1.8	11

#	Article	IF	Citations
37	Risk of obstetric anal sphincter injury among women who birth vaginally after a prior caesarean section: A stateâ€wide cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, , .	1.1	4
38	Maternal mortality at the National Referral Hospital in Honiara, Solomon Islands over a fiveâ€year period. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 183-187.	0.4	6
39	Combination methotrexate and gefitinib: A potential medical treatment for inoperable nontubal ectopic pregnancy. Journal of Obstetrics and Gynaecology Research, 2020, 46, 531-535.	0.6	3
40	Novel approaches to combat preeclampsia: from new drugs to innovative delivery. Placenta, 2020, 102, 10-16.	0.7	30
41	MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia. Scientific Reports, 2020, 10, 18077.	1.6	11
42	Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia. Pregnancy Hypertension, 2020, 22, 86-92.	0.6	15
43	Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth. PLoS ONE, 2020, 15, e0238700.	1.1	12
44	Preventable stillbirths in the Solomon Islands â€“ A hidden tragedy. The Lancet Regional Health - Western Pacific, 2020, 5, 100050.	1.3	2
45	Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. Nature Communications, 2020, 11, 2411.	5.8	37
46	Aurora kinase mRNA expression is reduced with increasing gestational age and in severe early onset fetal growth restriction. Placenta, 2020, 95, 53-61.	0.7	7
47	Circulating Delta-like homolog 1 (DLK1) at 36 weeks is correlated with birthweight and is of placental origin. Placenta, 2020, 91, 24-30.	0.7	9
48	Accuracy of clinical suspicion of growth restriction at term despite a normal growth ultrasound: A retrospective cohort study. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 568-573.	0.4	0
49	Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia. Placenta, 2020, 95, 78-83.	0.7	12
50	Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction. Pregnancy Hypertension, 2020, 20, 83-91.	0.6	33
51	Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth. BMC Medicine, 2020, 18, 145.	2.3	25
52	Reduced growth velocity from the mid-trimester is associated with placental insufficiency in fetuses born at a normal birthweight. BMC Medicine, 2020, 18, 395.	2.3	19
53	Title is missing!. , 2020, 15, e0238700.		0
54	Title is missing!. , 2020, 15, e0238700.		0

#	Article	IF	Citations
55	Title is missing!. , 2020, 15, e0238700.		0
56	Title is missing!. , 2020, 15, e0238700.		0
57	Title is missing!. , 2020, 15, e0238700.		0
58	Title is missing!. , 2020, 15, e0238700.		0
59	Bloodâ€based biomarkers in the maternal circulation associated with fetal growth restriction. Prenatal Diagnosis, 2019, 39, 947-957.	1.1	15
60	Prediction of adverse maternal outcomes in preeclampsia at term. Pregnancy Hypertension, 2019, 18, 75-81.	0.6	9
61	Systematic review of areca (betel nut) use and adverse pregnancy outcomes. International Journal of Gynecology and Obstetrics, 2019, 147, 292-300.	1.0	11
62	Screening circulating proteins to identify biomarkers of fetal macrosomia. BMC Research Notes, 2019, 12, 587.	0.6	0
63	Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling. Placenta, 2019, 87, 53-57.	0.7	9
64	Death associated protein kinase 1 (DAPK-1) is increased in preeclampsia. Placenta, 2019, 88, 1-7.	0.7	9
65	Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin. Scientific Reports, 2019, 9, 235.	1.6	8
66	A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 Trial): study protocol. BMJ Open, 2019, 9, e025809.	0.8	34
67	Proton Pump Inhibitors and Preeclampsia Risk Among 157â€‰720 Women. Hypertension, 2019, 73, 1097-1103.	1.3	22
68	Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction. EBioMedicine, 2019, 41, 636-648.	2.7	38
69	Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia. Pregnancy Hypertension, 2019, 16, 16-25.	0.6	11
70	The untapped potential of placenta-enriched molecules for diagnostic and therapeutic development. Placenta, 2019, 84, 28-31.	0.7	30
71	The incidence of hypertensive disorders of pregnancy following sperm donation in IVF: an Australian state-wide retrospective cohort study. Human Reproduction, 2019, 34, 2541-2548.	0.4	11
72	Predictive Value of the Signs and Symptoms Preceding Eclampsia. Obstetrics and Gynecology, 2019, 134, 677-684.	1.2	13

#	Article	IF	Citations
73	EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble) Tj ETQq1 1 0.784314 rgBT /Overlock	1.5	50
74	Reply. American Journal of Obstetrics and Gynecology, 2019, 220, 207.	0.7	0
75	High-dose compared with low-dose oxytocin for induction of labour of nulliparous women at term. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 362-368.	0.7	4
76	A Systematic Review of Proton Pump Inhibitors for the Prevention and Treatment of Preeclampsia and Gestational Hypertension. Open Journal of Obstetrics and Gynecology, 2019, 09, 21-28.	0.1	1
77	Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. EBioMedicine, 2018, 29, 166-176.	2.7	4
78	Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia. Pregnancy Hypertension, 2018, 13, 1-6.	0.6	8
79	Accurately Predicting the Risk of Serious Maternal Morbidity in Preterm Preeclampsia. Hypertension, 2018, 71, 569-571.	1.3	0
80	A multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3): trial protocol. Trials, 2018, 19, 643.	0.7	5
81	Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome. Pregnancy Hypertension, 2018, 14, 125-130.	0.6	1
82	EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia. Pregnancy Hypertension, 2018, 14, 115-120.	0.6	6
83	Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36Âweeksâ€™ gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study. BMC Pregnancy and Childbirth, 2018, 18, 354.	0.9	26
84	ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia. American Journal of Pathology, 2018, 188, 1749-1753.	1.9	36
85	Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000â€“10,000â€¯IU/L: Phase II Open Label, Single Arm Multi-Centre Trial. EBioMedicine, 2018, 33, 276-281.	2.7	8
86	Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia. PLoS ONE, 2018, 13, e0187082.	1.1	34
87	Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial. American Journal of Obstetrics and Gynecology, 2018, 219, 388.e1-388.e17.	0.7	64
88	Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction â€“ implications for treating preeclampsia. PLoS ONE, 2018, 13, e0188845.	1.1	31
89	Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis. Molecular Human Reproduction, 2017, 23, 69-78.	1.3	59
90	Variable effect of maternal oral glucose load on circulating cell-free placental mRNAs. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 501-503.	0.7	1

#	Article	IF	Citations
91	Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 635-639.	0.7	13
92	Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction. Placenta, 2017, 51, 1-9.	0.7	20
93	Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction. Hypertension, 2017, 69, 457-468.	1.3	118
94	Preventing preeclampsia with aspirin: does dose or timing matter?. American Journal of Obstetrics and Gynecology, 2017, 216, 95-97.	0.7	30
95	Enoxaparin for the prevention of preeclampsia andÂintrauterine growth restriction in women withÂaÂhistory:ÂaÂrandomized trial. American Journal of Obstetrics and Gynecology, 2017, 216, 296.e1-296.e14.	0.7	66
96	Reply. American Journal of Obstetrics and Gynecology, 2017, 217, 383-384.	0.7	0
97	The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer. Biomedical Reports, 2017, 6, 319-322.	0.9	26
98	Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction â€“ implications as a preeclampsia treatment. Scientific Reports, 2017, 7, 1819.	1.6	49
99	Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro. Reproductive Sciences, 2017, 24, 1245-1252.	1.1	11
100	Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta. Hypertension, 2017, 70, 1014-1024.	1.3	27
101	sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies?. Pregnancy Hypertension, 2017, 10, 18-21.	0.6	8
102	Reduced growth velocity across the third trimester is associated with placental insufficiency in fetuses born at a normal birthweight: a prospective cohort study. BMC Medicine, 2017, 15, 164.	2.3	60
103	Placental Insufficiency in Fetuses That Slow in Growth but Are Born Appropriate for Gestational Age: A Prospective Longitudinal Study. PLoS ONE, 2016, 11, e0142788.	1.1	43
104	A comparison of sample collection methods for quantifying cell-free fetal neurodevelopment transcripts in amniotic fluid. BMC Research Notes, 2016, 9, 335.	0.6	2
105	ATF3 is a negative regulator of inflammation in human fetal membranes. Placenta, 2016, 47, 63-72.	0.7	15
106	Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta. Placenta, 2016, 48, 110-118.	0.7	12
107	Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. BMC Pregnancy and Childbirth, 2016, 16, 117.	0.9	47
108	Measuring circulating placental RNAs to non-invasively assess the placental transcriptome and to predict pregnancy complications. Prenatal Diagnosis, 2016, 36, 997-1008.	1.1	31

#	Article	IF	Citations
109	Loss of Akt increases soluble endoglin release from endothelial cells but not placenta. Pregnancy Hypertension, 2016, 6, 95-102.	0.6	6
110	Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production1. Biology of Reproduction, 2016, 94, 59.	1.2	17
111	Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeksâ€™ gestation. American Journal of Obstetrics and Gynecology, 2016, 214, 521.e1-521.e8.	0.7	21
112	Expectant management of severe preterm preeclampsia: a comparison of maternal and fetal indications for delivery. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 3821-3826.	0.7	7
113	Metformin as a prevention and treatment for preeclampsia: effectsÂonÂsoluble fms-like tyrosine kinase 1 and soluble endoglinÂsecretion and endothelial dysfunction. American Journal of Obstetrics and Gynecology, 2016, 214, 356.e1-356.e15.	0.7	156
114	Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia. Placenta, 2016, 48, 72-79.	0.7	9
115	Impairment of Angiogenic Sphingosine Kinase-1/Sphingosine-1-Phosphate Receptors Pathway in Preeclampsia. PLoS ONE, 2016, 11, e0157221.	1.1	19
116	A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin. Pregnancy Hypertension, 2015, 5, 294-297.	0.6	0
117	Diagnosing a miscarriage. BMJ, The, 2015, 351, h4769.	3.0	2
118	Double blind, randomised, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE Trial): a study protocol. BMJ Open, 2015, 5, e008211.	0.8	41
119	Treatment of Early-Onset Preeclampsia With Continuous Positive Airway Pressure. Obstetrics and Gynecology, 2015, 125, 1106-1109.	1.2	26
120	Paternal obesity in a rodent model affects placental gene expression in a sex-specific manner. Reproduction, 2015, 149, 435-444.	1.1	63
121	Chorioamnionitis Occurring in Women With Preterm Rupture of the Fetal Membranes Is Associated With a Dynamic Increase in mRNAs Coding Cytokines in the Maternal Circulation. Reproductive Sciences, 2015, 22, 852-859.	1.1	20
122	Sofalcone Upregulates the Nuclear Factor (Erythroid-Derived 2)â€"Like 2/Heme Oxygenase-1 Pathway, Reduces Soluble fmsâ€"Like Tyrosine Kinase-1, and Quenches Endothelial Dysfunction. Hypertension, 2015, 65, 855-862.	1.3	44
123	Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14. Placenta, 2015, 36, 932-937.	0.7	9
124	Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E936-E945.	1.8	40
125	Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia. Hypertension, 2015, 66, 687-697.	1.3	154
126	Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity. Hypertension, 2015, 66, 1251-1259.	1.3	70

#	Article	IF	Citations
127	Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. Hypertension, 2015, 66, 1073-1081.	1.3	32
128	YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. Molecular and Cellular Endocrinology, 2015, 413, 202-208.	1.6	26
129	Molecular diagnostics and therapeutics for ectopic pregnancy. Molecular Human Reproduction, 2015, 21, 126-135.	1.3	19
130	A Bioplex Analysis of Cytokines and Chemokines in First Trimester Maternal Plasma to Screen for Predictors of Miscarriage. PLoS ONE, 2014, 9, e93320.	1.1	17
131	Combination gefitinib and methotrexate treatment for non-tubal ectopic pregnancies: a case series. Human Reproduction, 2014, 29, 1375-1379.	0.4	19
132	Measuring hypoxia-induced RNA in maternal blood: a new way to identify critically hypoxic fetusesin utero?. Expert Review of Molecular Diagnostics, 2014, 14, 509-511.	1.5	13
133	Peptides do not prevent cleavage of endoglin to produce soluble endoglin. Pregnancy Hypertension, 2014, 4, 255-258.	0.6	0
134	Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin. Pregnancy Hypertension, 2014, 4, 287-295.	0.6	52
135	Galectin-7 acts as an adhesion molecule during implantation and increased expression is associated with miscarriage. Placenta, 2014, 35, 195-201.	0.7	26
136	Placental SEMA3B expression is not altered in severe early onset preeclampsia. Placenta, 2014, 35, 1102-1105.	0.7	6
137	Stability of absolute copy number of housekeeping genes in preeclamptic and normal placentas, as measured by digital PCR. Placenta, 2014, 35, 1106-1109.	0.7	19
138	Soluble endoglin production is upregulated by oxysterols but not quenched by pravastatin in primary placental and endothelial cells. Placenta, 2014, 35, 724-731.	0.7	37
139	PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia. Reproduction, Fertility and Development, 2014, 26, 351.	0.1	39
140	Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study. Reproductive Biology and Endocrinology, 2013, 11, 40.	1.4	7
141	Using a decline in serum hCG between days 0â€“4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study. BMC Pregnancy and Childbirth, 2013, 13, 30.	0.9	28
142	The role of leukemia inhibitory factor in tubal ectopic pregnancy. Placenta, 2013, 34, 1014-1019.	0.7	28
143	The use of miRNA microarrays for the analysis of cancer samples with global miRNA decrease. Rna, 2013, 19, 876-888.	1.6	52
144	Quantifying circulating hypoxia-induced RNA transcripts in maternal blood to determine in uterofetal hypoxic status. BMC Medicine, 2013, 11, 256.	2.3	28

#	Article	IF	Citations
145	MT-MMPs in pre-eclamptic placenta: Relationship to soluble endoglin production. Placenta, 2013, 34, 168-173.	0.7	18
146	PLAC4 is upregulated in severe early onset preeclampsia and upregulated with syncytialisation but not hypoxia. Placenta, 2013, 34, 256-260.	0.7	8
147	Targeted Nanoparticle Delivery of Doxorubicin Into Placental Tissues to Treat Ectopic Pregnancies. Endocrinology, 2013, 154, 911-919.	1.4	53
148	Quantifying mRNA coding growth genes in the maternal circulation to detect fetal growth restriction. American Journal of Obstetrics and Gynecology, 2013, 209, 133.e1-133.e9.	0.7	17
149	Effects of Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, on Human Placental Cell Growth. Obstetrics and Gynecology, 2013, 122, 737-744.	1.2	25
150	Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol. BMJ Open, 2013, 3, e002902.	0.8	10
151	Corin, an enzyme with a putative role in spiral artery remodeling, is up-regulated in late secretory endometrium and first trimester decidua. Human Reproduction, 2013, 28, 1172-1180.	0.4	27
152	Placental Specific mRNA in the Maternal Circulation Are Globally Dysregulated in Pregnancies Complicated by Fetal Growth Restriction. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E429-E436.	1.8	54
153	MHR welcomes high-quality basic reproductive research around pregnancy. Molecular Human Reproduction, 2013, 19, 709-710.	1.3	2
154	Circulating RNA coding genes regulating apoptosis in maternal blood in severe early onset fetal growth restriction and pre-eclampsia. Journal of Perinatology, 2013, 33, 600-604.	0.9	18
155	Combination Gefitinib and Methotrexate Compared With Methotrexate Alone to Treat Ectopic Pregnancy. Obstetrics and Gynecology, 2013, 122, 745-751.	1.2	29
156	Effects of Maternal Obstructive Sleep Apnoea on Fetal Growth: A Prospective Cohort Study. PLoS ONE, 2013, 8, e68057.	1.1	94
157	Maternal Serum Macrophage Inhibitory Cytokine-1 as a Biomarker for Ectopic Pregnancy in Women with a Pregnancy of Unknown Location. PLoS ONE, 2013, 8, e66339.	1.1	6
158	Plasma MIC-1 and PAPP-A Levels Are Decreased among Women Presenting to an Early Pregnancy Assessment Unit, Have Fetal Viability Confirmed but Later Miscarry. PLoS ONE, 2013, 8, e72437.	1.1	22
159	Circulating MicroRNAs in Maternal Blood as Potential Biomarkers for Fetal Hypoxia In-Utero. PLoS ONE, 2013, 8, e78487.	1.1	80
160	Ultrasound Reference Chart Based on IVF Dates to Estimate Gestational Age at 6â€“9 weeksâ€™ Gestation. ISRN Obstetrics & Gynecology, 2012, 2012, 1-6.	1.2	6
161	The Evolution of Methotrexate as a Treatment for Ectopic Pregnancy and Gestational Trophoblastic Neoplasia: A Review. ISRN Obstetrics & Gynecology, 2012, 2012, 1-8.	1.2	35
162	Diagnostic Accuracy of Maternal Serum Macrophage Inhibitory Cytokine-1 and Pregnancy-Associated Plasma Protein-A at 6â€“10 Weeks of Gestation to Predict Miscarriage. Obstetrics and Gynecology, 2012, 119, 1000-1008.	1.2	32

#	Article	IF	Citations
163	Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage. Journal of Reproductive Immunology, 2012, 95, 46-49.	0.8	31
164	MMP-14 Is Expressed in Preeclamptic Placentas and Mediates Release of Soluble Endoglin. American Journal of Pathology, 2012, 180, 888-894.	1.9	63
165	Has increased clinical experience with methotrexate reduced the direct costs of medical management of ectopic pregnancy compared to surgery?. BMC Pregnancy and Childbirth, 2012, 12, 98.	0.9	11
166	MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin. PLoS ONE, 2012, 7, e39864.	1.1	17
167	Evaluation of ADAM-12 as a Diagnostic Biomarker of Ectopic Pregnancy in Women with a Pregnancy of Unknown Location. PLoS ONE, 2012, 7, e41442.	1.1	13
168	Prognostic value of human chorionic gonadotropin levels 4â€ƒdays after a single dose of methotrexate for ectopic pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 506-507.	1.1	1
169	Serum Concentrations of Soluble Flt-1 Are Decreased among Women with a Viable Fetus and No Symptoms of Miscarriage Destined for Pregnancy Loss. PLoS ONE, 2012, 7, e32509.	1.1	14
170	Severe Early-Onset Preeclampsia Is Not Associated with a Change in Placental Catechol O-Methyltransferase (COMT) Expression. American Journal of Pathology, 2011, 178, 2484-2488.	1.9	26
171	Of Leaves and Butterflies. Obstetrics and Gynecology, 2011, 118, 1169-1173.	1.2	8
172	Placental expression of a novel primate-specific splice variant of sFlt-1 is upregulated in pregnancies complicated by severe early onset pre-eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 1268-1271.	1.1	31
173	Decline in Î²hCG levels between days 0 and 4 after a single dose of methotrexate for ectopic pregnancy predicts treatment success: a retrospective cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 1665-1668.	1.1	28
174	Association between maternal serum cytokine profiles at 7-10 weeks' gestation and birthweight in small for gestational age infants. American Journal of Obstetrics and Gynecology, 2011, 204, 415.e1-415.e12.	0.7	28
175	Placental HtrA3 Is Regulated by Oxygen Tension and Serum Levels Are Altered during Early Pregnancy in Women Destined to Develop Preeclampsia. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 403-411.	1.8	33
176	Characterization of Symptoms Immediately Preceding Eclampsia. Obstetrics and Gynecology, 2011, 118, 995-999.	1.2	47
177	Measurement of mRNA Transcripts of Very High Placental Expression in Maternal Blood as Biomarkers of Preeclampsia. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1807-E1815.	1.8	39
178	Is Fetal Growth Restriction Associated with a More Severe Maternal Phenotype in the Setting of Early Onset Pre-Eclampsia? A Retrospective Study. PLoS ONE, 2011, 6, e26937.	1.1	46
179	Rational Design of Immunostimulatory siRNAs. Molecular Therapy, 2010, 18, 785-795.	3.7	66
180	Association Between Twin Discordance at 6â€“9 Weeks' of Gestation and Birthweight Complications. Twin Research and Human Genetics, 2010, 13, 389-392.	0.3	5

#	Article	IF	Citations
181	Two Corpora Lutea Seen at 6â€“13 Weeks' Gestation Infers Dizygosity Among Spontaneous Same-Sexed Dichorionic Twins. Twin Research and Human Genetics, 2009, 12, 180-182.	0.3	3
182	Predicting Perinatal Outcome Through Changes in Umbilical Artery Doppler Studies After Antenatal Corticosteroids in the Growth-Restricted Fetus. Obstetrics and Gynecology, 2009, 113, 636-640.	1.2	45
183	Thyroid function and autoantibody status among women who spontaneously deliver under 35â€ƒweeks of gestation. Clinical Endocrinology, 2009, 71, 892-895.	1.2	17
184	Corpus luteum across the first trimester: size and laterality as observed by ultrasound. Fertility and Sterility, 2008, 90, 1844-1847.	0.5	15
185	TLR7 Is Involved in Sequence-Specific Sensing of Single-Stranded RNAs in Human Macrophages. Journal of Immunology, 2008, 180, 2117-2124.	0.4	145
186	Miscarriage Risk for Asymptomatic Women After a Normal First-Trimester Prenatal Visit. Obstetrics and Gynecology, 2008, 111, 710-714.	1.2	37
187	Highly specific and sensitive rise in Days 14â€“17 pro-Î±C inhibin with clinical pregnancy after frozen embryo transfer with ovulatory cycles. Human Reproduction, 2007, 22, 2249-2253.	0.4	1
188	Maternal serum activin A and the prediction of intrauterine growth restriction. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2006, 46, 97-101.	0.4	11
189	Activin A, hypoxia and the prediction of obstetric outcomes. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2006, 46, 146-147.	0.4	3
190	Association Between Low Day 16 hCG and Miscarriage After Proven Cardiac Activity. Obstetrics and Gynecology, 2006, 107, 300-304.	1.2	10
191	Increased Day 15â€“17 Serum Pro-Î±C Inhibin Levels Specific to Successful Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4464-4468.	1.8	1
192	First trimester levels of inhibins and activin A in normal and failing pregnancies. Clinical Endocrinology, 2004, 60, 484-490.	1.2	18
193	Fetal activin A: associations with labour, umbilical artery pH and neonatal outcome. BJOG: an International Journal of Obstetrics and Gynaecology, 2004, 111, 326-330.	1.1	5
194	Author reply to letter from Dr Kafali. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2004, 44, 172-172.	0.4	0
195	Determining zygosity in early pregnancy by ultrasound. Ultrasound in Obstetrics and Gynecology, 2004, 23, 36-37.	0.9	14
196	Maternal serum and amniotic fluid levels of macrophage inhibitory cytokine 1 in Down syndrome and chromosomally normal pregnancies. Prenatal Diagnosis, 2004, 24, 224-226.	1.1	4
197	Low levels of pregnancy-associated plasma protein-A in asymptomatic women destined for miscarriage. Fertility and Sterility, 2004, 82, 1468-1470.	0.5	18
198	Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet, The, 2004, 363, 129-130.	6.3	86

#	Article	IF	Citations
199	Hysteroscopy under general anaesthesia, a near painless procedure. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2003, 43, 344-345.	0.4	4
200	Inhibins and activins: clinical advances in reproductive medicine. Clinical Endocrinology, 2003, 58, 115-127.	1.2	34
201	Maternal and Foetal Activin A Levels: Associations with Normal and Abnormal Labour. Placenta, 2002, 23, 570-574.	0.7	9
202	Dizygotic twin survival in early pregnancy. Nature, 2002, 416, 142-142.	13.7	13
203	Cord blood sampling at delivery: do we need to always collect from both vessels?. BJOG: an International Journal of Obstetrics and Gynaecology, 2002, 109, 1175-1177.	1.1	23
204	Delayed presentation of uterine perforation and haemorrhagic shock 10 days after surgical termination of pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2001, 41, 335-336.	0.4	5
205	Dizygotic to monozygotic twinning ratio at The Royal Women's Hospital, Melbourn 1947â€“1997, compared with Australian national twinning incidence. Twin Research and Human Genetics, 2000, 3, 12-16.	1.5	0
206	Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost. Contraception, 2000, 62, 297-303.	0.8	60
207	Dizygotic to monozygotic twinning ratio at The Royal Womenâ€™s Hospital, Melbourne 1947â€“1997, compared with Australian national twinning incidence. Twin Research and Human Genetics, 2000, 3, 12-16.	1.5	2
208	Use of dizygotic to monozygotic twinning ratio as a measure of fertility. Lancet, The, 1997, 349, 843-845.	6.3	67
209	Leather, oranges, dead pigs and needlestick injuries. Medical Journal of Australia, 1996, 165, 683-683.	0.8	1